Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.
Vertex Pharmaceuticals Inc, in collaboration with Kissei Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.
Ding
Changhai
C
Menzies Research Institute, University of Tasmania, Hobart, Tasmania 7000, Australia. changhai.ding@utas.edu.au
D000208:Acute Disease; D000284:Administration, Oral; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D004341:Drug Evaluation; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D010330:Patents as Topic; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013577:Syndrome; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D010671:Phenylurea Compounds; C517771:VX 702; D048051:p38 Mitogen-Activated Protein Kinases